Although currently limited, Michelle Petri, MD, MPH, explains that the drug market for treating systemic lupus erythematosus (SLE) is growing. Dr Petri explains that because SLE is a heterogeneous disease that manifests in patients in many different ways, new agents to treat SLE will be classified into a series of different categories.
Dr Petri continues the discussion by exploring the future roles of these new agents which leads the panelists into a conversation about the costs of these treatment options.
Hugh Fatodu, RPh, MBA, and Dr Petri conclude that without proper data that review the long-term outcomes of agents for the treatment of SLE, it is difficult to estimate any economic benefits or advantages.
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More